|
|
Vaccine Detail
|
Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA |
| Vaccine Information |
- Vaccine Name: Incomplete Freund's adjuvant (IFA) alone, or a melanoma vaccine in IFA
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007623
- Type: multipepted
- Status: Clinical trial
- Preparation: At a primary vaccine site, all patients received a multi-peptide melanoma vaccine in IFA. At a replicate vaccine site, which was biopsied, group 1 received IFA only; group 2 received vaccine in IFA. Lymphocytes isolated from replicate vaccine site microenvironments (VSME) were compared to time-matched peripheral blood mononuclear cells (Salerno et al., 2013).
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: VSME had fewer naïve and greater proportions of effector memory CD8(+) T cells (TCD8), majority of TCD8 within the VSME were activated (CD69(+)), with a concentration of antigen-specific (tetramer(pos)) cells in the VSME, minimal IFN-γ production in response to peptide stimulation and few tetramer(pos) cells producing IFN-γ (Salerno et al., 2013).
|
| References |
Salerno et al., 2013: Salerno EP, Shea SM, Olson WC, Petroni GR, Smolkin ME, McSkimming C, Chianese-Bullock KA, Slingluff CL Jr. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide. Cancer immunology, immunotherapy : CII. 2013; 62(7); 1149-1159. [PubMed: 23657629].
|
|
